Ahmed to Baerveldt glaucoma drainage device exchange in pediatric patients.
Ahmed implant
Baerveldt implant
Childhood glaucoma
Glaucoma drainage device
Journal
BMC ophthalmology
ISSN: 1471-2415
Titre abrégé: BMC Ophthalmol
Pays: England
ID NLM: 100967802
Informations de publication
Date de publication:
11 Jul 2023
11 Jul 2023
Historique:
received:
21
02
2023
accepted:
07
07
2023
medline:
13
7
2023
pubmed:
12
7
2023
entrez:
11
7
2023
Statut:
epublish
Résumé
There is no consensus and few reports as to the surgical management of encapsulated Ahmed glaucoma drainage devices (GDD) which no longer control intraocular pressure (IOP), especially within the pediatric population. The purpose of this study was to report outcomes of exchanging the Ahmed GDD for a Baerveldt GDD in children with refractory glaucoma. Retrospective review of children (< 18yrs) who underwent removal of Ahmed FP7 and placement of Baerveldt 350 (2016-2021) with ≥ 3-month follow-up. Surgical success was defined as IOP 5-20 mmHg without additional IOP-lowering surgeries or visually devastating complications. Outcomes included change in best-corrected visual acuity (BCVA), intraocular pressure (IOP), and number of glaucoma medications. Twelve eyes of 10 patients underwent superotemporal Ahmed FP7 to Baerveldt 350 GDD exchange at 8.8 ± 3.6 years. Time to Ahmed failure was 2.7 ± 1.9 years with 1-, 3-, and 5-year survival rates of 83% with a 95% CI[48,95], 33% with a 95% CI[10, 59], and 8% with a 95% CI[0, 30]. At final follow-up (2.5 ± 1.8 years), success rate for Baerveldt 350 GDDs was 75% (9 of 12 eyes) with 1 and 3-yr survival rates of 100% and 71% with 95% CI[25,92], respectively. IOP (24.1 ± 2.9 vs. 14.9 ± 3.1 mmHg) and number of glaucoma medications (3.7 ± 0.7 vs. 2.7 ± 1.1) were significantly decreased (p < 0.004). BCVA remained stable. Two eyes required cycloablation and 1 eye developed a retinal detachment. Ahmed removal with Baerveldt placement can improve IOP control with fewer medications in cases of refractory pediatric glaucoma. However, more eyes with greater follow-up are required to determine long-term outcomes.
Sections du résumé
BACKGROUND
BACKGROUND
There is no consensus and few reports as to the surgical management of encapsulated Ahmed glaucoma drainage devices (GDD) which no longer control intraocular pressure (IOP), especially within the pediatric population. The purpose of this study was to report outcomes of exchanging the Ahmed GDD for a Baerveldt GDD in children with refractory glaucoma.
METHODS
METHODS
Retrospective review of children (< 18yrs) who underwent removal of Ahmed FP7 and placement of Baerveldt 350 (2016-2021) with ≥ 3-month follow-up. Surgical success was defined as IOP 5-20 mmHg without additional IOP-lowering surgeries or visually devastating complications. Outcomes included change in best-corrected visual acuity (BCVA), intraocular pressure (IOP), and number of glaucoma medications.
RESULTS
RESULTS
Twelve eyes of 10 patients underwent superotemporal Ahmed FP7 to Baerveldt 350 GDD exchange at 8.8 ± 3.6 years. Time to Ahmed failure was 2.7 ± 1.9 years with 1-, 3-, and 5-year survival rates of 83% with a 95% CI[48,95], 33% with a 95% CI[10, 59], and 8% with a 95% CI[0, 30]. At final follow-up (2.5 ± 1.8 years), success rate for Baerveldt 350 GDDs was 75% (9 of 12 eyes) with 1 and 3-yr survival rates of 100% and 71% with 95% CI[25,92], respectively. IOP (24.1 ± 2.9 vs. 14.9 ± 3.1 mmHg) and number of glaucoma medications (3.7 ± 0.7 vs. 2.7 ± 1.1) were significantly decreased (p < 0.004). BCVA remained stable. Two eyes required cycloablation and 1 eye developed a retinal detachment.
CONCLUSIONS
CONCLUSIONS
Ahmed removal with Baerveldt placement can improve IOP control with fewer medications in cases of refractory pediatric glaucoma. However, more eyes with greater follow-up are required to determine long-term outcomes.
Identifiants
pubmed: 37434139
doi: 10.1186/s12886-023-03074-1
pii: 10.1186/s12886-023-03074-1
pmc: PMC10334620
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
310Informations de copyright
© 2023. The Author(s).
Références
J Glaucoma. 2018 May;27(5):421-428
pubmed: 29462014
J Glaucoma. 2022 Jun 1;31(6):468-477
pubmed: 34930874
J Glaucoma. 2016 Jun;25(6):e620-4
pubmed: 26091182
Eur J Ophthalmol. 2021 May;31(3):1070-1078
pubmed: 32354227
Surv Ophthalmol. 2017 Sep - Oct;62(5):591-610
pubmed: 28188728
Am J Ophthalmol. 2003 Dec;136(6):1001-8
pubmed: 14644209
Acta Ophthalmol. 2015 Jun;93(4):e248-53
pubmed: 25363490
Eur J Ophthalmol. 2019 Jan;29(1):44-51
pubmed: 29587488
Arch Ophthalmol. 1992 Apr;110(4):480-5
pubmed: 1562252
J Glaucoma. 2019 Nov;28(11):989-996
pubmed: 31567908
Int Ophthalmol. 2016 Jun;36(3):347-53
pubmed: 26334729
Am J Ophthalmol. 2017 Apr;176:118-126
pubmed: 28104418
Ophthalmol Glaucoma. 2021 Jan-Feb;4(1):63-70
pubmed: 32707177
Clin Ophthalmol. 2020 Mar 04;14:693-705
pubmed: 32184556
Am J Ophthalmol. 2000 Apr;129(4):455-60
pubmed: 10764852
Br J Ophthalmol. 2015 Dec;99(12):1718-24
pubmed: 26024673
Eur J Ophthalmol. 2007 Nov-Dec;17(6):928-37
pubmed: 18050119
Ophthalmology. 2006 Jun;113(6):913-7
pubmed: 16751034
J AAPOS. 2022 Oct;26(5):232.e1-232.e7
pubmed: 36122872
Ophthalmic Surg. 1993 Nov;24(11):723-9
pubmed: 8290209
J Glaucoma. 2020 Oct;29(10):948-951
pubmed: 32590448
Can J Ophthalmol. 2017 Jun;52(3):295-301
pubmed: 28576212
J AAPOS. 2022 Jun;26(3):122.e1-122.e6
pubmed: 35550861
Ophthalmology. 1997 Dec;104(12):2117-20
pubmed: 9400773